跳轉至內容
Merck
全部照片(1)

重要文件

SML0536

Sigma-Aldrich

依法韦伦

≥98% (HPLC)

同義詞:

依法韦伦, (4S)-6-氯-4-(2-环丙基乙炔基)-1,4-二氢-4-(三氟甲基)-2H-3,1-苯并恶嗪-2-酮

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C14H9ClF3NO2
CAS號碼:
分子量::
315.67
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

品質等級

化驗

≥98% (HPLC)

形狀

powder

光學活性

[α]/D -90 to -100°, c = 1 in methanol

顏色

white to beige

溶解度

DMSO: 15 mg/mL, clear

儲存溫度

−20°C

SMILES 字串

ClC1=CC=C2C([C@@](C#CC3CC3)(C(F)(F)F)OC(N2)=O)=C1

InChI

1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1

InChI 密鑰

XPOQHMRABVBWPR-ZDUSSCGKSA-N

尋找類似的產品? 前往 產品比較指南

一般說明

具有Sustiva商品名的依法韦仑是一种含有苯和恶嗪-2-酮发色团的多环芳烃。

應用

依法韦仑已用于:
  • 评估其抗猪内源性逆转录病毒(PERV)活性
  • 细胞毒性检测
  • 通过结合时间密度泛函理论(TD-DFT)和光谱计算的方法,研究依法韦仑的溶质-溶剂效应

生化/生理作用

依法韦仑是一种非核苷类逆转录酶抑制剂(NNRTI)。它是一种抗HIV药物,常用于AIDs治疗的联合疗法。它是用于治疗人类免疫缺陷病毒(HIV)1型的高效抗逆转录病毒疗法(HAART)的一部分。
依法韦仑是一种非核苷类逆转录酶抑制剂(NNRTI);抗逆转录病毒。

特點和優勢

这种化合物是 ADME 毒性研究的特色产品。点击此处发现更多特色 ADME 毒性产品。在sigma.com/discover-bsm可了解更多关于生物活性小分子的其他研究领域。

法律資訊

Sustiva is a trademark of E. I. du Pont de Nemours and Company

訊號詞

Danger

危險聲明

危險分類

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Repr. 1B

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

未看到正確版本?

如果您需要一個特定的版本,您可以透過批號來尋找特定憑證。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Lawrence S U Lee et al.
Annals of the Academy of Medicine, Singapore, 41(12), 559-562 (2013-01-11)
Efavirenz is an inducer of drug metabolism enzymes. We studied the effect of efavirenz and ritonavir-boosted darunavir on serum unconjugated and conjugated bilirubin, as probes for UGT1A1 and bile transporters. Healthy volunteers were enrolled in a clinical trial. There were
Rochelle P Walensky et al.
Annals of internal medicine, 158(2), 84-92 (2013-01-16)
U.S. HIV treatment guidelines recommend branded once-daily, 1-pill efavirenz-emtricitabine-tenofovir as first-line antiretroviral therapy (ART). With the anticipated approval of generic efavirenz in the United States, a once-daily, 3-pill alternative (generic efavirenz, generic lamivudine, and tenofovir) will decrease cost but may
L B Avery et al.
Antimicrobial agents and chemotherapy, 57(3), 1409-1414 (2013-01-09)
Efavirenz (EFV) is one of the most commonly prescribed antiretroviral drugs (ARVs) for the treatment of HIV. Highly protein-bound drugs, like EFV, have limited central nervous system (CNS) penetration when measured using total drug concentration gradients between blood plasma (BP)
A combined TD-DFT and spectroscopic investigation of the solute?solvent interactions of efavirenz.
Jordaan M A, et al.
Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy, 157, 204-210 (2016)
Gregory P Bisson et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 56(8), 1165-1173 (2013-01-31)
The burden of Cryptococcus neoformans in cerebrospinal fluid (CSF) predicts clinical outcomes in human immunodeficiency virus (HIV)-associated cryptococcal meningitis (CM) and is lower in patients on antiretroviral therapy (ART). This study tested the hypothesis that initiation of ART during initial

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務